Good evidence begets good policy: Or so it should be

Transfusion

Volumn 52, Issue 3, 2012, Pages 463-465

  Custer, Brian S ^a  

^a BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD SAFETY; BLOOD TRANSFUSION; COST EFFECTIVENESS ANALYSIS; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; INFECTION; INFECTIOUS COMPLICATION; REVIEW;

BLOOD BANKS; BLOOD DONORS; HUMANS; MASS SCREENING; VIRUS DISEASES;

EID: 84858248721     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2012.03560.x     Document Type: Review

References (17)

1. Borkent-Raven BA, Janssen MP, van der Poel CL, Bonsel GJ, van Hout BA,. Cost-effectiveness of additional blood screening tests in the Netherlands. Transfusion 2012; 52: 478-88.
2. Custer B, Hoch JS,. Cost-effectiveness analysis: what it really means for transfusion medicine decision making. Transfus Med Rev 2009; 23: 1-12.
3. AuBuchon JP,. Lessons learned from decision analysis. Transfusion 1996; 36: 755-60.
4. AuBuchon JP,. Cost-effectiveness of new blood safety technologies. Dev Biol (Basel) 2000; 102: 211-5.
5. Custer B,. Economic analyses of blood safety and transfusion medicine interventions: a systematic review. Transfus Med Rev 2004; 18: 127-43. (Pubitemid 38501238)
6. Kamper-Jorgensen M, Hjalgrim H, Edgren G, Titlestad K, Ullum H, Shanwell A, Reilly M, Melbye M, Nyrén O, Rostgaard K,. Expensive blood safety initiatives may offer less benefit than we think. Transfusion 2010; 50: 240-2.
7. van Hulst M, Smit Sibinga CT, Postma MJ,. Health economics of blood transfusion safety-focus on sub-Saharan Africa. Biologicals 2002; 38: 53-8.
8. Manca A, Sculpher MJ, Goeree R,. The analysis of multinational cost-effectiveness data for reimbursement decisions: a critical appraisal of recent methodological developments. Pharmacoeconomics 2010; 28: 1079-96.
9. Herwaldt BL, Linden JV, Bosserman E, Young C, Olkowska D, Wilson M,. Transfusion-associated babesiosis in the United States: a description of cases. Ann Intern Med 2011; 155: 509-19.
10. AuBuchon JP, Birkmeyer JD, Busch MP,. Cost-effectiveness of expanded human immunodeficiency virus-testing protocols for donated blood. Transfusion 1997; 37: 45-51. (Pubitemid 27068939)
11. Busch MP, Korelitz JJ, Kleinman SH, Lee SR, AuBuchon JP, Schreiber GB,. Declining value of alanine aminotransferase in screening of blood donors to prevent posttransfusion hepatitis B and C virus infection. The Retrovirus Epidemiology Donor Study. Transfusion 1995; 35: 903-10. (Pubitemid 26141041)
12. Jackson BR, Busch MP, Stramer SL, AuBuchon JP,. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion 2003; 43: 721-9. (Pubitemid 36629116)
13. Marshall DA, Kleinman SH, Wong JB, AuBuchon JP, Grima DT, Kulin NA, Weinstein MC,. Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States. Vox Sang 2004; 86: 28-40. (Pubitemid 38200453)
14. Custer B, Busch MP, Marfin AA, Petersen LR,. The cost-effectiveness of screening the U.S. blood supply for West Nile virus. Ann Intern Med 2005; 143: 486-92.
15. Agapova M, Busch MP, Custer B,. Cost-effectiveness of screening the US blood supply for Trypanosoma cruzi. Transfusion 2010; 50: 2220-32.
16. Borkent-Raven BA, Janssen MP, van der Poel CL, de Wit GA, Bonsel GJ, van Hout BA,. Cost-effectiveness of additional hepatitis B virus nucleic acid testing of individual donations or minipools of six donations in the Netherlands. Transfusion 2009; 49: 311-9.
17. Janssen MP, van der Poel CL, Buskens E, Bonneux L, Bonsel GJ, van Hout BA,. Costs and benefits of bacterial culturing and pathogen reduction in the Netherlands. Transfusion 2006; 46: 956-65. (Pubitemid 43800914)